Amir Hashemi-Meshkini
Overview
Explore the profile of Amir Hashemi-Meshkini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rezaee M, Karimzadeh I, Hashemi-Meshkini A, Zeighami S, Bazyar M, Lotfi F, et al.
Value Health Reg Issues
. 2024 Apr;
42:100982.
PMID: 38663058
Objectives: Metastatic prostate cancer is the most common malignant cancer and the second leading cause of death due to various types of cancer among men after lung cancer. This study...
2.
Hashemi-Meshkini A, Tajik A, Ayati N, Nikfar S, Koochak R, Yaghoubifard S, et al.
J Tehran Heart Cent
. 2023 Aug;
18(2):94-101.
PMID: 37637281
Background: The present study aimed to determine the cost-effectiveness of ticagrelor compared with clopidogrel in Iranian patients with acute coronary syndrome (ACS). Methods: A 1-year decision tree model combined with...
3.
Reshadat-Hajiabad T, Khajavi A, Hosseinpour A, Bojdy A, Hashemi-Meshkini A, Varmaghani M
BMC Health Serv Res
. 2023 Mar;
23(1):251.
PMID: 36918880
Background: Since the start of the AIDS outbreak, the human immunodeficiency virus (HIV) has infected about 84.2 million people, and approximately 40.1 million people have died due to AIDS-related diseases....
4.
Kokabisaghi F, Hashemi-Meshkini A, Obewal A, Ghavami V, Javan-Noughabi J, Shabanikiya H, et al.
Daru
. 2022 Nov;
30(2):343-350.
PMID: 36385235
Purpose: Affordable access to quality medicines is a critical target of global efforts to achieve universal health coverage. The aim of this study is to measure the affordability and accessibility...
5.
Hashemi-Meshkini A, Koochak R, Nikfar S, Rezaei-Darzi E, Yaghoubifard S
J Res Pharm Pract
. 2022 Oct;
11(1):1-7.
PMID: 36277970
Objective: In this study, we assess population-level data of COVID-19 treatments in Iran compared to Ministry of Health (MOH)-published guidelines to gain a better insight into the quality of care...
6.
Hashemi-Meshkini A, Zekri H, Karimi-Yazdi H, Zaboli P, Sahraian M, Nikfar S
Iran J Neurol
. 2019 Mar;
17(3):123-128.
PMID: 30886679
Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to...
7.
Keshavarz K, Lotfi F, Sanati E, Salesi M, Hashemi-Meshkini A, Jafari M, et al.
Daru
. 2017 Oct;
25(1):23.
PMID: 29070077
Background: Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with...
8.
Teimouri M, Farzadfar F, Soudi Alamdari M, Hashemi-Meshkini A, Adibi Alamdari P, Rezaei-Darzi E, et al.
Iran J Pharm Res
. 2017 Feb;
15(Suppl):113-123.
PMID: 28228810
Data about the prevalence of communicable and non-communicable diseases, as one of the most important categories of epidemiological data, is used for interpreting health status of communities. This study aims...
9.
Hashemi-Meshkini A, Nikfar S, Glaser E, Jamshidi A, Hosseini S
Value Health Reg Issues
. 2016 Nov;
9:42-48.
PMID: 27881258
Objectives: To analyze the cost-effectiveness of two common treatment strategies in Iran, comparing infliximab plus methotrexate with tocilizumab plus methotrexate in patients with rheumatoid arthritis with inadequate response to traditional...
10.
Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri H, et al.
J Res Pharm Pract
. 2016 Aug;
5(3):155-61.
PMID: 27512704
The pharmaceutical legal framework is a very important infrastructure in achieving predefined goals in pharmaceutical sector: Accessibility, quality, and rational use of medicine. This study aims to review the current...